Kenostart SD 3000ppm

Main information

  • Trade name:
  • Kenostart SD 3000ppm
  • Pharmaceutical form:
  • Cutaneous liquid
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Kenostart SD 3000ppm
    Greece
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • DISINFECTANTS
  • Therapeutic area:
  • Cattle Lactating

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0244/001
  • Authorization date:
  • 10-06-2011
  • EU code:
  • UK/V/0244/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:January2012

AN.02052/2010

Page1of4

SUMMARYOFPRODUCTCHARACTERISTICS

1. Nameoftheveterinarymedicinalproduct:

ForallCMSexceptFranceandSweden

KENOSTARTSPRAYANDDIP3mg/gTeatDiporSpraySolutionforcattle(dairy)

France

KENOSPRAY3000,3mg/gTeatDiporSpraySolutionforcattle(dairy)

Sweden

Kenosprayvet.,3mg/gTeatDiporSpraySolutionforcattle(dairy)

2. Qualitativeandquantitativecomposition:

AvailableIodine,3mg/g

Forafulllistofexcipients,seesection6.1.

3. Pharmaceuticalform:

TeatDiporSpraySolution

Darkbrownsolution

4. Clinicalparticulars:

4.1 Targetspecies:

Cattle(dairy).

4.2 Indicationsforuse,specifyingthetargetspecies:

Teatdisinfectionaspartofapreventionstrategyformastitisincattle.

4.3 Contraindications:

Donotuseincaseofhypersensitivitytotheactivesubstanceortoanyofthe

excipients.

4.4 Specialwarningforeachtargetspecies

Ensureudderandteatsarecleananddrybeforethenextmilking.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Forexternaluseonly.

Useforthetreatmentofteatswithcutaneouslesionsmaydelaywound-healing

process.Itisrecommendedtodiscontinuethetreatmentuntilthelesionsare

healed.

Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Avoidcontactwitheyes.Ifsplashedintheeye,rinsewithcleanrunningwater

andseekmedicaladvice.

Incaseofingestion,drinklargequantitiesofwaterandseekmedicalattention

immediately.

Revised:January2012

AN.02052/2010

Page2of4

Keepawayfromfoodandanimalfeed.

Washhandsafteruse.

Whenusedasaspray,avoidworkinginthespraymist.Thosewhoare

hypersensitivetoiodineshouldavoidusingthisproduct.

Otherprecautions

None.

4.6 Adversereactions(frequencyandseriousness):

Repeatedexposuretoiodinecanleadtoiodineallergy.Allergicreactionsto

iodinemaybecomeapparentasallergicskinreactionbutalsoasanaphylactic

shockinrarecases.

4.7 Useduringpregnancy,lactationorlay:

Canbeusedduringpregnancyandlactation.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction:

Donotmixwithotherchemicals,teatdisinfectantsorteatcareproducts.

4.9 Amountstobeadministeredandadministrationroute:

Theproductissuitablefordippingorsprayingimmediatelyaftereachmilking.

Theveterinarymedicinalproductissuppliedreadytouseasateatdipor

spray.Ifadipcupisused,itshouldholdatleast5mlofveterinarymedicinal

product.Diptheteatsimmediatelyaftermilkingeachcow.Ensurethattheteat

iscompletelycoveredtothreequartersofitslength.

Fortheteatspraying,spraytheentiresurfaceofeachteatwiththeveterinary

medicinalproductimmediatelyaftermilking.Thedipcuporsprayershouldbe

replenishedasnecessary.Thedipcuporsprayershouldbeemptiedafter

milkingandwashedbeforereused.Theproductismeanttobeusedasapost-

milkingteatdiporsprayuptotwotimesperday.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary:

Notapplicable.Thisveterinarymedicinalproductisfortopicalapplication,

significantabsorptiondoesnotoccur.

4.11Withdrawalperiods:

Meat&offal:zerodays

Milk:zerodays

5. Pharmacologicalproperties:

Pharmacotherapeuticgroup:Dermatologicals,antiseptic,disinfectantofiodine-based

compoundclass

ATCVetcode:QD08AG03

5.1 Pharmacodynamicproperties:

Free(molecular)iodineactivityisbasedonaredoxmechanism(theoxidising

effectdestroysmicro-organisms)andtheformingofsaltswithbacterialprotein

Theredoxreactioninvolvesvariouscellwallconstituents,whichareirreversibly

transformed.Itappearsthatsulfhydryllinkages,inbacterialcellwall

components,arespecificallyaffectedbytheIodine.

Revised:January2012

AN.02052/2010

Page3of4

Whenusedasanantiseptic,Iodinesolutionsreactwiththeorganicmatterof

bacteriaandvirusestorenderthemharmless.

Theproductisanantiseptic.Ithasbeendemonstratedtobeefficientagainst

bacteriacausingmastitis.IthasbeentestedaccordingtoEuropeanStandards

EN1656(fieldconditions)againstStaphylococcusaureus,Escherichiacoli,

Streptococcusagalactiae,Streptococcusdysgalactiae,Streptococcusuberis

andCorynebacteriumbovis.Thesestudieswerecarriedoutin2005atCIRLAM

laboratory.

5.2 Pharmacokineticparticulars:

Thepublishedliteratureindicatesthatiodinecoatedontotheskinrapidly

interactswithanyorganicmaterialpresentleavingverylittlefreeiodinefor

absorptionthroughtheepidermis.Ithasalsobeenreportedthatonlyasmall

increaseinserumiodineconcentrationisfoundafterteatdipping.

6 Pharmaceuticalparticulars:

6.1 Listofexcipients

Glycerol

Sorbitol70%

Sodiumhydrogensulphite40%

EthoxylatedLanolin50%

SodiumIodate

SodiumChloride

SodiumHydroxide30%

SodiumIodide

XanthanGum

Alcohol(C12-C15)11MoleEthoxylate

CitricAcid

WaterPurified

6.2 Incompatibilities:

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmust

notbemixedwithotherveterinarymedicinalproducts.

6.3 Shelflife:

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:2years

Shelflifeafterfirstopeningtheimmediatepackaging:6months

6.4 Specialprecautionsforstorage:

Storeintheoriginalcontainer

Keepthecontainertightlyclosed

Protectfromfrost

Iftheveterinarymedicinalproducthasfrozen,thawinawarmplaceandshake

wellbeforeuse

Protectfromlight

Revised:January2012

AN.02052/2010

Page4of4

6.5 Natureandcompositionofimmediatepackaging:

Adarkbrownliquidsolutioncontainedin1,5,10,20,25,60litres,greyhigh-

densitypolyethylenedrumswithHDPEcapsando-ringsealsand200litres,in

bluehigh-densitypolyethylenedrumswithHDPEcapsando-ringseals.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinal

productsorwastematerialsderivedfromtheuseofsuchproducts,if

appropriate:

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductshouldbedisposedofinaccordancewithlocal

requirements.

Theproductshouldnotenterwatercoursesasthismaybedangerousforfish

andotheraquaticorganisms.

7 Marketingauthorisationholder:

CIDLINESNV

Waterpoortstraat,2

8900IEPER

BELGIUM

8 Marketingauthorisationnumber

UK:VM22136/4001

Transportemergency:ForUKtransportemergenciesonlyphone01865407333

IE:VPAN°10792/2/1

LM(LicensedMerchant)

9 Dateofthefirstauthorisation

06September2006

10 Dateofrevisionofthetext

January2012

7-8-2018

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Over the last few years, seaweed has become increasingly common on our plates. Fresh, dried or as a food supplement, its iodine content varies and can sometimes be high. ANSES assessed the risk of excess iodine intake from the consumption of seaweed-based products. In view of the non-negligible risk of exceeding the upper limit of safe intake for iodine, the Agency advises against the consumption of seaweed and seaweed-based food supplements by certain at-risk populations, and recommends that regular con...

France - Agence Nationale du Médicament Vétérinaire

There are no news related to this product.